Mechanisms for an abnormal radionuclide left ventricular ejection fraction response to exercise in patients with chronic, severe aortic regurgitation

To clarify the mechanisms for an abnormal radionuclide left ventricular (LV) ejection fraction response to exercise in patients with chronic, severe aortic regurgitation (AR), we studied seven control patients and 21 patients with AR. We used exercise radionuclide angiography and catheterization of the right and left sides of the heart to obtain a calculation of LV chamber elastance. The control and AR groups had similar heart rates, systolic blood pressure responses to exercise, and exercise durations. In both patient groups, LV end-diastolic volume did not change with exercise. In contrast to the decrease in LV end-systolic volume (p < 0.05) and increase in LV ejection fraction (p < 0.01) in the control group, LV end-systolic volume in the patients with AR increased, resulting in little change in their LV ejection fraction. By stepwise multiple regression analysis, the radionuclide LV ejection fraction at peak exercise in patients with AR was determined by the LV chamber elastance, LV end-systolic volume, and stroke volume at peak exercise (cumulative r = 0.79, p < 0.02); the change in radionuclide LV ejection fraction from rest to peak exercise was determined by the corresponding change in systemic vascular resistance, regurgitant index, and LV end-diastolic and end-systolic volumes (cumulative r = 0.88, p < 0.02). These data demonstrate that in patients with AR, the radionuclide LV ejection fraction at peak exercise is principally determined by the cumulative effects of chronic, severe AR on LV systolic chamber performance, and the change in radionuclide LV ejection fraction from rest to peak exercise is principally established by peripheral vascular responses. (Am Heart J 1992;123:453.)

Richard E. Stewart, MD, Milton D. Gross, MD, and Mark R. Starling, MD.
Ann Arbor, Mich.

A noninvasive technique that could follow the sequential changes in left ventricular (LV) size and performance in patients with chronic, severe aortic regurgitation (AR) who have minimal or no symptoms and thus that could guide the selection of patients for cardiac catheterization and aortic valve replacement would be helpful. Exercise radionuclide angiography has been proposed for this purpose. It has been shown that this noninvasive technique can quantitate the changes in LV size and performance between rest and peak exercise. Moreover, it has been suggested that this technique may be useful for identifying those who will have progression of their symptoms and who will need aortic valve replacement among patients with AR who have minimal or no symptoms.

The precise pathophysiologic mechanism responsible for an abnormal radionuclide LV ejection fraction response to exercise in these patients is, however, a controversial topic. Some believe that an abnormal radionuclide LV ejection fraction response to exercise in patients with AR is related to loading conditions or the peripheral vascular changes that occur with exercise. In contrast, other investigators have suggested that the chronic effects of AR on LV systolic performance or contractility play an integral role in determining how the left ventricle responds to exercise. This investigation was designed to clarify the mechanisms for an abnormal radionuclide LV ejection fraction response to exercise in patients with...
Table I. Baseline hemodynamic values

<table>
<thead>
<tr>
<th></th>
<th>Controls (n = 7)</th>
<th>Aortic regurgitation (n = 21)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR</td>
<td>71 ± 7</td>
<td>71 ± 8</td>
<td>N.S.</td>
</tr>
<tr>
<td>SBP (mm Hg)</td>
<td>143 ± 22</td>
<td>147 ± 20</td>
<td>N.S.</td>
</tr>
<tr>
<td>RAP (mm Hg)</td>
<td>7 ± 3</td>
<td>7 ± 3</td>
<td></td>
</tr>
<tr>
<td>PCWP (mm Hg)</td>
<td>26 ± 2</td>
<td>12 ± 6</td>
<td></td>
</tr>
<tr>
<td>LVEDP (mm Hg)</td>
<td>12 ± 4</td>
<td>18 ± 10</td>
<td>N.S.</td>
</tr>
<tr>
<td>LVSP (mm Hg)</td>
<td>129 ± 32</td>
<td>143 ± 30</td>
<td>N.S.</td>
</tr>
<tr>
<td>+dP/dt max (mm Hg/sec)</td>
<td>1077 ± 442</td>
<td>1239 ± 327</td>
<td>N.S.</td>
</tr>
<tr>
<td>E max (mm Hg/ml)</td>
<td>4.94 ± 1.14</td>
<td>1.82 ± 1.24</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

HR, Heart rate; SBP, systolic blood pressure; RAP, right atrial pressure; PCWP, pulmonary capillary wedge pressure; LVEDP, left ventricular end-diastolic pressure; LVSP, left ventricular systolic pressure; +dP/dt max, maximum rate of change of LV pressure; E max, chamber elastance.

chronic, severe AR and therefore to possibly lead to an understanding of why an abnormal response to exercise is predictive of symptomatic and hemodynamic deterioration.

METHODS

Patients. The patient population consisted of seven patients in the control group and 21 patients with chronic, severe AR. The seven patients in the control group were men with an age range of 40 to 72 years (mean 56 ± 10 years). No patient in the control group had experienced a myocardial infarction, and all had normal findings on electrocardiograms, chest roentgenograms, and physical examinations. These patients had been referred for cardiac catheterizations so that their chest pain syndromes could be evaluated. They were all found to have normal coronary anatomy, LV volumes, ejection fractions, and wall motion. The patients with AR consisted of 20 men and one woman with an age range of 33 to 78 years (mean 56 ± 14 years). Four patients were in clinical class I, 11 were in class II, six were in class III, and no patient was in class IV. Thus the majority of patients with AR had minimal or no symptoms. At the time of referral 14 patients had LV hypertrophy on an electrocardiogram, and eight patients had cardiomegaly on a chest radiograph. These patients had evidence on physical examination of moderate to severe AR. All patients had been referred so that the hemodynamic significance of their AR could be defined. All were found to have normal coronary anatomy, angiographic 3+ or 4+ AR, and no evidence of significant aortic stenosis (aortic valve gradient of 10 mm Hg or less).

Protocol. All patients provided written informed consent on forms approved by the Institutional Review Boards at the University of Michigan or VA Medical Centers. All β-adrenergic-blocking and calcium-channel-blocking agents, vasodilators, inotropic agents, diuretics, and nitrates were discontinued 24 to 48 hours before the initiation of the studies. The day before the cardiac catheterization, each patient, using a braked bicycle ergometer, underwent a supine bicycle exercise radionuclide angiogram. The work load was begun at 200 kilopond-meters (kpm) and was progressively increased in increments of 100 kpm every 3 minutes to a symptom limit. Gated equilibrium radionuclide angiograms were obtained at each patient's rest and peak exercise. On the following day a diagnostic catheterization of the right and left sides of the heart documented resting intracardiac pressures, cardiac output, and normal coronary anatomy. Micromanometer LV pressures and radionuclide angiograms were then obtained under baseline conditions and after methoxamine or nitroprusside infusions to achieve multiple additional loading conditions with right atrial pacing to maintain heart rate constant.8

Radionuclide angiography. The gated equilibrium radionuclide angiograms were acquired with the use of a Siemens Basicam (Siemens Medical Systems Inc., Iselin, N.J.) fitted with a low-energy all-purpose collimator. All studies were obtained after in vivo red blood cell labeling with 30 mCi technetium 99m for 30 msec frames throughout the cardiac cycle for 250 cardiac cycles. Midway through each radionuclide acquisition, a 2 ml blood sample was drawn. The blood samples were later counted for 2 minutes, and the time delay between acquisition and counting of the blood samples was recorded. At the completion of exercise or cardiac catheterization, distance measurements were obtained for each patient to determine the LV geometric center for attenuation correction.

Attenuation-corrected radionuclide LV volumes were calculated frame by frame by use of background-subtracted, hand-drawn, region-of-interest count data; decay-corrected blood sample counts; and attenuation correction as previously validated in this laboratory.9 Right ventricular end-diastolic and end-systolic counts were obtained by use of a modification of the method of Maddahi et al.10 We have used this method to calculate right ventricular (RV) volumes for comparison to those obtained from biplane contrast cineventriculography11 and to calculate RV volumes and ejection fractions in patients with RV infarction.12 We used these data to calculate LV regurgitant index (RI) as RI = (LVEDC-LVESC)/(RVEDC-RVESC), where EDC represents end-diastolic counts at maximum ventricular volume and ESC represents end-systolic counts at minimum ventricular volume for the LV and RV from the hand-drawn regions of interest.

Cardiac catheterization. After coronary arteriography and cineventriculography were performed in the control
LV maximum time-varying elastance ($E_{max}$) was defined as the maximum slope obtained from the linear regression of isochronal pressure-volume data points from each pressure-volume loop. $E_{max}$ has been proposed as a relatively load-independent index of contractility. This is probably valid when $E_{max}$ is measured in the same heart after pharmacologic interventions, which either positively or negatively affect contractility. However, when $E_{max}$ is calculated in different hearts, it may be affected by several factors other than contractility. Accordingly, in this investigation $E_{max}$ is used to represent net LV systolic chamber performance.

Several hemodynamic parameters were calculated from the radionuclide data at rest and peak exercise. The “effective” LV stroke volume was calculated as $SV = (LVEDV - LVESV)/RI$, where EDV and ESV represent radionuclide LV end-diastolic and end-systolic volumes and RI represents LV regurgitant index. “Effective” is used in this context as that portion of the total LV stroke output that does not contribute to regurgitant volume and thus would be effectively perfusing the peripheral tissues. Cardiac output (CO) was then calculated as $CO = SV \times HR$, where $SV$ represents “effective” LV stroke volume and $HR$ represents heart rate. The systemic vascular resistance (SVR) was calculated as $SVR = (mBP/CO) \times 80$ dynes/sec-cm$^5$, where $mBP$ represents mean brachial artery pressure determined as diastolic blood pressure (BP) plus one third of (systolic BP - diastolic BP).

**Table II. Exercise hemodynamic values**

<table>
<thead>
<tr>
<th></th>
<th>Controls (n = 7)</th>
<th>Aortic regurgitation (n = 21)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exercise duration (min)</td>
<td>12.6 ± 4.0</td>
<td>12.0 ± 3.5</td>
<td>N.S.</td>
</tr>
<tr>
<td>Peak HR</td>
<td>125 ± 18</td>
<td>127 ± 20</td>
<td>N.S.</td>
</tr>
<tr>
<td>Peak SBP (mm Hg)</td>
<td>203 ± 26</td>
<td>197 ± 26</td>
<td>N.S.</td>
</tr>
<tr>
<td>Rest LVEDV (ml)</td>
<td>151 ± 41</td>
<td>303 ± 183</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Peak LVEDV (ml)</td>
<td>147 ± 35</td>
<td>313 ± 182</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Rest LVESV (ml)</td>
<td>69 ± 24</td>
<td>165 ± 112</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Peak LVESV (ml)</td>
<td>50 ± 13*</td>
<td>177 ± 129</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Rest LVEF (%)</td>
<td>53 ± 7</td>
<td>50 ± 11</td>
<td>N.S.</td>
</tr>
<tr>
<td>Peak LVEF (%)</td>
<td>63 ± 7**</td>
<td>48 ± 12</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Rest CO (L/min)</td>
<td>5.8 ± 1.7</td>
<td>5.6 ± 1.6</td>
<td>N.S.</td>
</tr>
<tr>
<td>Peak CO (L/min)</td>
<td>11.5 ± 2.5**</td>
<td>10.6 ± 6.9**</td>
<td>N.S.</td>
</tr>
<tr>
<td>Rest SV (ml)</td>
<td>81 ± 18</td>
<td>73 ± 36</td>
<td>N.S.</td>
</tr>
<tr>
<td>Peak SV (ml)</td>
<td>97 ± 27</td>
<td>92 ± 58</td>
<td>N.S.</td>
</tr>
<tr>
<td>Rest RI</td>
<td>--</td>
<td>2.5 ± 1.9</td>
<td>--</td>
</tr>
<tr>
<td>Peak RI</td>
<td>--</td>
<td>2.1 ± 1.1</td>
<td>--</td>
</tr>
<tr>
<td>Rest SVR (dynes/sec-cm$^2$)</td>
<td>1242 ± 365</td>
<td>1870 ± 889</td>
<td>N.S.</td>
</tr>
<tr>
<td>Peak SVR (dynes/sec-cm$^2$)</td>
<td>824 ± 183*</td>
<td>1426 ± 966</td>
<td>N.S.</td>
</tr>
</tbody>
</table>

HR, Heart rate; SBP, systolic blood pressure; LVESV, left ventricular end systolic volume; LVEF, left ventricular ejection fraction; CO, cardiac output; SV, effective stroke volume; RI, regurgitant index; SVR, systemic vascular resistance.

*p < 0.05 vs rest values.

**p < 0.01 vs rest values.

group and additional ascending aortography was performed in the patients with AR, a bipolar pacing catheter was placed into the right atrium of each patient to maintain heart rate constant, and a precalibrated micromanometer catheter (Millar Instruments, Houston, Texas) was positioned to measure LV pressure. Hemodynamic recordings were obtained with an Electronics for Medicine VR-12, (PPG Biomedical Systems, Lenexa, Kan.) or Micor physiologic recorder, (Micor, Inc. Allison Park, Pa.) at 100 mm/sec paper speed. They included the simultaneous recording of an electrocardiographic lead (II), micromanometer LV and aortic pressure, and the first derivative of LV pressure, $dP/dt$, at a variable sampling frequency. Interpolation of these hand-digitized pressure (dP/dt). These hemodynamic recordings were obtained for 10 to 20 cardiac cycles at the beginning, middle, and end of each radionuclide acquisition.

The LV pressure waveforms were averaged and the average LV pressure waveforms were hand digitized with a Calcomp 9100 indutance-digitizing surface (resolution 0.02 mm) (Calcomp, Anaheim, Calif.) interfaced to an IBM XT (IBM Corp., Armonk, NY.) beginning at the peak of the R wave of the simultaneously recorded electrocardiogram. This program yields instantaneous LV pressure and the first derivative of LV pressure, $dP/dt$, at a variable sampling frequency. Interpolation of these hand-digitized LV pressure data was then performed to obtain instantaneous LV pressures that coincided with the midpoint of each radionuclide frame so that isochronal LV pressure and volume data were available for further analysis.

**Calculation of maximum time-varying elastance and other derived hemodynamic parameters.** The micromanometer LV pressures were matched to their corresponding radionuclide LV volumes for each loading condition and then plotted to obtain multiple pressure-volume loops. The LV maximum time-varying elastance ($E_{max}$) was defined as the maximum slope obtained from the linear regression of isochronal pressure-volume data points from each pressure-volume loop.

**Statistical analysis.** All data are expressed as the mean ± 1 SD. Nonpaired $t$ tests were used to compare the rest and peak exercise. The change in hemodynamic parameters from rest to peak exercise between the control patients and patients with AR. Paired $t$ tests were used to compare the LV size and performance measures at rest and peak exercise within each patient group. Correlation ma-
Fig. 1. The average LV end-diastolic volumes (left panel), end-systolic volumes (center panel), and ejection fractions (right panel) for the control groups (closed boxes) and the patients with chronic, severe AR (open boxes) are shown at rest and peak exercise. Significant differences between the rest and peak exercise values for the control and AR groups are noted.

Fig. 2. The average rest and peak exercise values for the control patients and patients with chronic, severe AR are shown for "effective" stroke volume (left panel), cardiac output (center panel), and systemic vascular resistance (right panel). The format is similar to Fig. 1, and significant differences are noted.

RESULTS

Baseline hemodynamic data. At the time of cardiac catheterization, 10 patients with AR had angio- graphic +4 AR and the remaining 11 patients had +3 AR. The heart rate averaged 71 ± 7 beats/min and the right atrial and pulmonary capillary wedge pressures averaged 7 ± 3 and 12 ± 6 mm Hg, respectively. The mean cardiac output was 5.6 ± 1.6 L/min. The micromanometer LV end-diastolic and end-systolic pressures averaged 18 ± 10 and 143 ± 30 mm Hg, respectively, and the average (+) maximum dP/dt was 1239 ± 327 mm Hg/sec. The LV E_max averaged 1.82 ± 1.24 mm Hg/ml, and it was less than that in the control group (4.94 ± 1.14 mm Hg/ml, p < 0.001, Table I).

Exercise hemodynamic data. The mean rest and peak exercise hemodynamic data for the control and AR groups are shown in Table II, and they are compared in Figs. 1 and 2. The average heart rate, systolic blood pressure, and pressure-rate product at rest and
peak exercise in the control and AR groups did not
do differ significantly. Consequently, the changes in
these values did not differ between the two patient
groups. The average exercise duration in the two
groups were similar.

The LV end-diastolic and end-systolic volumes
(LVEDV and LVESV, respectively) were larger in
the AR group than in the control group, both at rest
\( (p < 0.05 \text{ for both}) \) and at peak exercise \( (p < 0.05 \text{ for both}) \). The changes in LVEDV in the two patient
groups were similar. In contrast, the changes in
LVESV in the control group differed from those in
the AR group because LVESV decreased in the con-
trol group \( (p < 0.05 \text{ for both}) \) and increased in the AR
group. Consequently, although there was no differ-
ce in LV ejection fraction at rest, it differed for
each group at peak exercise \( (p < 0.01) \). This occurred
because there was a significant increase in LV eje-
tion fraction \( (p < 0.01) \) in the control group, but
there was no change in LV ejection fraction from rest
to peak exercise in the AR group (Fig. 1).

In the patients with AR the regurgitant index at
rest averaged \( 2.5 \pm 1.9 \). It decreased slightly, but it
was statistically unchanged, at peak exercise
\( (2.1 \pm 1.1) \). Although the cardiac output was some-
what less in the AR group than in the control group
at rest, it did not differ significantly between the
groups. In both patient groups, cardiac output in-
creased significantly at peak exercise \( (p < 0.01 \text{ for }
control and } p < 0.01 \text{ for AR}) \). Consequently, the
change in cardiac output was similar in both patient
groups. The systemic vascular resistance was higher
in the AR group than in the control group at rest
\( (1870 \pm 889 \text{ vs } 1242 \pm 365 \text{ dynes-sec/cm}^5) \), and val-
ues continued to differ at peak exercise \( (1426 \pm 966
\text{ vs } 824 \pm 183 \text{ dynes-sec/cm}^5) \). In the control patients
there was a decrease in systemic vascular resistance
from rest to peak exercise \( (p < 0.05) \), while there was
a small but insignificant decrease in systemic vascu-
lar resistance in the patients with AR (Fig. 2).

Determinants of LV ejection fraction response to ex-
ercise. To establish the determinants of the peak ex-
ercise LV ejection fraction and the change in LV
ejection fraction from rest to peak exercise, a corre-
lation matrix was established for each radionuclide
LV ejection fraction parameter. As shown in Fig. 3,
the peak exercise radionuclide LV ejection fraction
correlated with LVESV at peak exercise \( (r = -0.66,

Fig. 4. Similar to Fig. 3, the change in radionuclide LV ejection fraction from rest to peak exercise and the change in systemic vascular resistance (upper left panel), stroke volume (upper right panel), and LVESV (lower left panel) are shown. The individual data points, regression lines, and correlation coefficients are noted.

DISCUSSION

Borer et al. originally observed that during exercise the radionuclide LV ejection fraction increased from 57% to 71% in their control group, whereas it decreased from 47% to 38% in patients with AR who had symptoms, and it decreased from 62% to 57% in patients with AR who had no symptoms. He suggested that the radionuclide LV ejection fraction response to exercise might aid in the detection of LV dysfunction before symptoms and resting LV dysfunction developed and therefore might prove useful for the sequential evaluation of LV performance in these patients. In patients with chronic, severe AR who have no symptoms, the radionuclide LV ejection fraction response to exercise has subsequently been proved useful for predicting the eventual development of symptoms and the need for aortic valve surgery. The mechanism for an abnormal radionuclide LV ejection fraction response to exercise has, however, remained controversial.

Schueler et al. calculated the LV end-systolic pressure-volume relationship using radionuclide angiography in nine patients in a control group and 14 patients with AR, and compared it with the change in radionuclide LV ejection fraction from rest to peak exercise. In each patient with AR who had a normal LV end-systolic pressure-volume slope, the exercise LV ejection fraction increased six ejection fraction
units, whereas those patients with a reduced end-
systolic pressure-volume slope had a decrease in their
LV ejection fraction of five ejection fraction units. Subsequently, Shen et al. demonstrated that the change in radionuclide LV ejection fraction from rest to peak exercise in control and AR groups was linearly related to the slope of the LV end-systolic pressure-volume relationship. These investigators suggested that the change in radionuclide LV ejection fraction from rest to peak exercise might be related to the long-term effects of chronic, severe AR on LV contractile performance.

In contrast to these observations, other investigators have suggested that the radionuclide LV ejection fraction response to exercise in patients with AR may be determined by resting hemodynamic conditions. For example, Massie et al. reported that the change in radionuclide LV ejection fraction from rest to peak exercise was inversely related to pulmonary capillary wedge pressure \( r = -0.69, p < 0.01 \). In addition, Boucher et al. noted that a peak exercise pulmonary capillary wedge pressure of 15 mm Hg or more identified patients with AR who had lower radionuclide LV ejection fractions \( p < 0.01 \) and higher end-systolic volumes at peak exercise \( p < 0.01 \), compared to patients with AR who had more normal pulmonary capillary wedge pressures at peak exercise. Still other investigators have suggested that there is a relationship between the change in radionuclide LV ejection fraction from rest to peak exercise and LV stress, and the change in LVESV, cardiac output, or systemic vascular resistance. An increase in the radionuclide LV ejection fraction in patients with AR might therefore be associated with a lower resting LV peak or end systolic stress, a reduction in systemic vascular resistance, regurgitant index, and LVESV, and an improvement in cardiac output with exercise. Consequently, several hemodynamic mechanisms may be operative in patients with chronic, severe AR in determining how the left ventricle responds to the stress of exercise.

The data from the present investigation expands on these observations. It indicates that depending on whether the peak exercise LV ejection fraction or the change in LV ejection fraction from rest to peak exercise is used to evaluate LV performance, the hemodynamic determinants of these measures may differ in patients with AR. Notably, the peak exercise radionuclide LV ejection fraction was principally related to LV chamber performance, but the change in LV ejection fraction from rest to peak exercise was related to the corresponding change in peripheral vascular responses (i.e., systemic vascular resistance) and the resultant change in regurgitant index and LV volumes. Consequently, these data suggest that LV chamber performance might be the principal determinant of the peak exercise radionuclide LV ejection fraction, and that the change in LV ejection fraction from rest to peak exercise might be more affected by the response of the peripheral vasculature to chronic, severe LV volume overload.

Establishing the physiologic determinants of the peak exercise radionuclide LV ejection fraction or the change in LV ejection fraction from rest to peak exercise is necessary to understand how these data might contribute to the selection of patients with AR for cardiac catheterization and possible aortic valve surgery. It has been suggested that there is a natural hemodynamic progression in patients with chronic, severe volume overload that manifests initially as compensated, eccentric LV hypertrophy followed by LV systolic dysfunction in the absence of myocardial dysfunction and, finally, by the supervention of myocardial dysfunction. We have previously shown that LV chamber elastance, \( E_{\text{max}} \), may be abnormal in patients with AR in the absence of myocardial dysfunction. In those patients with AR who have an abnormal \( E_{\text{max}} \), the LV volume-to-mass ratio was increased, suggesting that inadequate, eccentric LV hypertrophy had developed and that LV shape had been altered. If the preload reserve of these patients is fully utilized, then an increase in LV load, whether it be induced pharmacologically or by exercise, might equate to either no change or a reduction in shortening, in comparison to patients with AR and normal \( E_{\text{max}} \) in whom these adaptive hemodynamic processes have presumably not been exhausted. Because the peak exercise radionuclide LV ejection fraction incorporates both the long-term effects of chronic, severe LV volume overload on myocardial performance and these other detrimental hemodynamic effects, it is not surprising that \( E_{\text{max}} \) is a major determinant of the peak exercise radionuclide LV ejection fraction.

Our data would also suggest that each patient with AR who has a peak exercise LV ejection fraction of less than 50% has abnormal LV chamber performance. This might be especially important in patients with AR who have no symptoms, in whom noninvasive techniques are commonly used to characterize sequential changes in LV systolic performance. Progression from a peak exercise LV ejection fraction of 50% or more to one that is less than 50% might be an early marker of those patients with AR who have progressed into a new hemodynamic phase in which LV chamber performance is impaired. Sequential changes in the peak exercise LV ejection fraction are particularly important, because an isolated peak exercise LV ejection fraction of less than 50% may represent LV systolic dysfunction due to
the existence of inadequate, eccentric LV hypertrophy and alterations of LV shape, myocardial dysfunction, or both. When these data are coupled with the recent observations of Siemieniuczuk et al., a hemodynamic explanation for the clinical and prognostic significance of an LV ejection fraction at peak exercise of 50% or less in patients with AR who have minimal or no symptoms can be appreciated.

The observation that the response of the peripheral vasculature to exercise may be an important determinant of the change in LV ejection fraction from rest to peak exercise in patients with AR substantiates the observations of other investigators. A reduction in systemic vascular resistance due to exercise, as observed in this investigation, produced a corollary reduction in regurgitant index and therefore a maintenance or improvement in LV ejection fraction from rest to peak exercise. The change in LV ejection fraction from rest to peak exercise appears to represent, therefore, the effects of chronic, severe volume overload on peripheral vascular adaptations. Recently, Borow et al. demonstrated that resting myocardial performance and myocardial reserve may be preserved in the type I diabetic group whether or not they have a normal increase from rest to peak exercise in radionuclide LV ejection fraction or if they have no change or a decrement in LV ejection fraction from rest to peak exercise. The change in LV ejection fraction from rest to peak exercise appears to represent, therefore, the effects of chronic, severe volume overload on peripheral vascular adaptations. The response of the peripheral vasculature to exercise may be an important determinant of the change in LV ejection fraction from rest to peak exercise in patients with AR who have minimal or no symptoms can be appreciated.

In this investigation, we used supine bicycle exercise to assess the changes in radionuclide LV volumes and ejection fractions. The response of the LV ejection fraction should be comparable whether upright or supine bicycle exercise is used. In general, the average response of the LVEDV and LVESV and LV ejection fractions in our patients with AR was comparable to those previously reported by other investigators, that is, all of the control patients demonstrated an appropriate increase in LV ejection fraction, while five of 21 patients with AR had an increase in LV ejection fraction. The remaining patients had either no change or a decrease in ejection fraction with exercise. The data in this investigation should therefore be comparable to previous studies in which supine bicycle exercise was used to assess the LV ejection fraction response to exercise in patients with AR.

We also used radionuclide angiography to calculate multiple hemodynamic parameters at rest and during peak exercise to compare with the radionuclide LV ejection fraction response to exercise. We have demonstrated that LV volume and ejection fractions can be obtained accurately with the use of an attenuation correction technique previously validated in this laboratory. Moreover, we employed a modification of the technique of Maddahi et al. to obtain right ventricular end-diastolic and end-systolic counts and ejection fraction. The LV regurgitant index, "effective" LV stroke volume and cardiac output, and systemic vascular resistance were then calculated both at rest and peak exercise. Importantly, we have used this approach to calculate right ventricular volumes for comparison to biplane cineventriculographic right ventricular volumes and to diagnosis and assess therapy of right ventricular infarction. The term effective should be clarified. We defined effective LV stroke volume and cardiac output as the beat and minute output, respectively, used to perfuse the peripheral vascular tissues. Consequently, total LV stroke or cardiac output was decremented by the regurgitant volume to calculate these hemodynamic parameters. The cardiac output calculated on the day before cardiac catheterization with the use of this radionuclide approach was similar to that obtained with the use of the thermodilution technique, suggesting that this approach should have provided reliable information about right and left ventricular performance, cardiac output, and systemic vascular resistance.

In conclusion, the data in this investigation suggest that the radionuclide LV ejection fraction during peak exercise is most strongly affected by LV chamber performance, and that the change in LV ejection fraction from rest to peak exercise is principally determined by peripheral vascular responses and their resultant effects on regurgitant index and LV volumes. Consequently, because the peak exercise LV ejection fraction reflects LV chamber performance and it has been shown to predict symptomatic deterioration in patients with AR, it might be an appropriate noninvasive exercise radionuclide parameter to follow for establishing the time period for invasive studies and possible aortic valve replacement.

We appreciate the assistance of Christina Brown, BS, Janet Petrusa, RN, Jacqueline Anderson, and Jacqueline LeRoy in the preparation of this manuscript.
REFERENCES


